Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

ADC Therapeutics

Thumbnail
December 17, 2020

Key upcoming clinical catalysts for biotech

Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.

Thumbnail
November 25, 2020

Bergenbio dream lives on, despite Genmab's broken Axl

Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.

Article image
Vantage logo
July 07, 2020

What pandemic? Biotech floats break records

After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.

Article image
Vantage logo
November 05, 2019

Daiichi's challenge to Seattle enters the legal realm

Article image
Vantage logo
August 01, 2019

Private European companies enjoy their own treasure bath

The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.

Article image
Vantage logo
July 09, 2019

The cash register rings for Biontech and ADC Therapeutics

Article image
Vantage logo
September 14, 2018

Antibody-drug conjugate resurgence continues with Lumoxiti

Article image
Vantage logo
August 08, 2018

J&J study halt reveals a crisis in follow-on antibody approaches

Vantage logo
May 22, 2018

Asco preview – A second wind for antibody-drug conjugates

Article image
Vantage logo
January 17, 2018

2017 rewrites the record books as venture funding accelerates

In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.

Vantage logo
November 02, 2017

Ash 2017 preview – Blueprint and Stemline celebrate

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.